Medically reviewed by Drugs.com. Last updated on Mar 1, 2019.
(lan REE oh tide)
- Lanreotide (Long-Acting Aqueous)
- Lanreotide Acetate
- Lanreotide Autogel
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Somatuline Depot: 120 mg/0.5 mL (0.5 mL); 60 mg/0.2 mL (0.2 mL); 90 mg/0.3 mL (0.3 mL)
Brand Names: U.S.
- Somatuline Depot
- Somatostatin Analog
Lanreotide is a synthetic octapeptide analogue of natural somatostatin which is a peptide inhibitor of multiple endocrine, neuroendocrine, and exocrine mechanisms. Lanreotide displays a greater affinity for somatostatin type 2 (SSTR2) and type 5 (SSTR5) receptors found in pituitary gland, pancreas, and growth hormone (GH) secreting neoplasms of pituitary gland and a lesser affinity for somatostatin receptors 1, 3, and 4. Lanreotide reduces GH secretion and also reduces the levels of insulin-like growth factor 1.
15.14 L (Trocóniz 2009)
Urine (<5% as unchanged drug); feces (<0.5% as unchanged drug)
Time to Peak
7 to 12 hours (Trocóniz 2009)
23 to 30 days
Special Populations: Renal Function Impairment
In patients with ESRD, there is approximately a 2-fold decrease in total serum clearance, with a consequent 2-fold increase in half-life and AUC.
Special Populations: Hepatic Function Impairment
A 30% reduction in clearance was observed in patients with moderate to severe hepatic impairment.
Special Populations: Elderly
Compared with healthy younger subjects, elderly subjects showed an 85% increase in half-life and a 65% increase in mean residence time.
Use: Labeled Indications
Acromegaly: Long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option (the treatment goal is to reduce growth hormone and insulin growth factor-1 levels to normal).
The Endocrine Society suggests use of a somatostatin analog in select patients preoperatively to reduce surgical risk from severe comorbidities and as initial adjuvant therapy in patients with persistent, significant disease (ie, moderate to severe signs/symptoms of growth hormone excess and without local mass effects) following surgery. Alternative agents are suggested for patients with mild disease postoperatively (Endocrine Society [Katznelson 2014]).
Carcinoid syndrome: Treatment of carcinoid syndrome in adults (to reduce the frequency of short acting somatostatin analog rescue therapy).
Gastroenteropancreatic neuroendocrine tumors: Treatment (to improve progression-free survival) of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
Hypersensitivity to lanreotide or any component of the formulation
Canadian labeling: Additional contraindications (not in the US labeling): Hypersensitivity to somatostatin or related peptides; complicated, untreated bile duct lithiasis
Acromegaly: SubQ: Initial dose: 90 mg once every 4 weeks for 3 months; after initial 3 months, continue monitoring and adjust dose as necessary based on clinical response of patient, growth hormone (GH) levels, and/or insulin-like growth factor 1 (IGF-1) levels as follows:
GH ≤1 ng/mL, IGF-1 normal, symptoms stable: Decrease dose to 60 mg once every 4 weeks; once stabilized on 60 mg once every 4 weeks, may consider regimen of 120 mg once every 6 or 8 weeks (extended-interval dosing)
GH >1 to 2.5 ng/mL, IGF-1 normal, symptoms stable: Continue 90 mg once every 4 weeks; once stabilized on 90 mg once every 4 weeks, may consider regimen of 120 mg once every 6 or 8 weeks (extended-interval dosing)
GH >2.5 ng/mL, IGF-1 elevated and/or uncontrolled symptoms: Increase dose to 120 mg once every 4 weeks. In some cases, individualized doses of 180 mg once every 4 weeks or 120 mg once every 3 weeks have been used successfully in partial responders (Giustina 2017).
Note: If clinical and/or biochemical response is inadequate at maximum dosage, consider combination therapy with pegvisomant or a dopamine agonist (eg, cabergoline) (Endocrine Society [Katznelson 2014]).
Carcinoid syndrome: SubQ: 120 mg once every 4 weeks (if already receiving lanreotide for treatment of gastroenteropancreatic neuroendocrine tumors [GEP-NETs], do not administer an additional dose for carcinoid syndrome)
GEP-NETs: SubQ: 120 mg once every 4 weeks until disease progression or unacceptable toxicity
Refer to adult dosing.
Allow to reach room temperature by removing sealed pouch from refrigerator 30 minutes prior to administration; keep in sealed pouch until just prior to administration. Product left in its sealed pouch at room temperature (<40°C [104°F]) for <24 hours may be returned to the refrigerator for storage and use at a later time. Lanreotide depot has a semi-solid phase with a gel-like viscous white to pale yellow appearance.
SubQ: Administer by deep subcutaneous injection (only) into superior outer quadrant of buttocks. Alternate injection sites between the right and left sides from one injection to the next. Remove sealed pouch from refrigerator 30 minutes prior to administration in order to reach room temperature. Keep pouch sealed until just prior to injection.
Store at 2°C to 8°C (36°F to 46°F). Protect from light; store in the original package.
Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol. Monitor therapy
Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy
Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy
Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents. Monitor therapy
Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents. Monitor therapy
Bromocriptine: Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations. Monitor therapy
Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Exceptions are discussed in separate monographs. Consider therapy modification
Codeine: Somatostatin Analogs may decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs. Monitor therapy
CycloSPORINE (Systemic): Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic). Consider therapy modification
Gallium Ga 68 Dotatate: Somatostatin Analogs may diminish the therapeutic effect of Gallium Ga 68 Dotatate. Specifically, a false negative PET scan may occur if Gallium GA 68 Dotatate is used during treatment with somatostatin analogs. Management: Imaging with gallium Ga 68 dotatate positron emission tomography (PET) should be performed just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate. Consider therapy modification
Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy
Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Monitor therapy
Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. Monitor therapy
Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. Monitor therapy
Lutetium Lu 177 Dotatate: Somatostatin Analogs may diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Specifically, the therapeutic effect of Lutetium Lu 177 Dotatate may be diminished if the timing of Somatostatin Analog administration is not carried out as recommended. Management: Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each lutetium Lu 177 dotatate dose. Administer short- and long-acting octreotide during treatment as recommended. See full monograph. Consider therapy modification
Macimorelin: Somatostatin Analogs may diminish the diagnostic effect of Macimorelin. Avoid combination
Maitake: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents. Monitor therapy
Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Pegvisomant: Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes. Monitor therapy
Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Monitor therapy
Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible. Monitor therapy
Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Consider therapy modification
Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. Consider therapy modification
Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents. Monitor therapy
Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Monitor therapy
Cardiovascular: Bradycardia (3% to 18%), hypertension (5% to 14%)
Central nervous system: Headache (5% to 16%)
Endocrine & metabolic: Weight loss (5% to 11%)
Gastrointestinal: Diarrhea (26% to 65%; dose related), abdominal pain (7% to 34%; dose related), vomiting (5% to 19%), flatulence (≤14%; dose related), nausea (9% to 11%)
Hematologic & oncologic: Anemia (3% to 14%)
Hepatic: Cholelithiasis (2% to 27%), gallbladder sludge (20%)
Immunologic: Antibody development (≤11%)
Local: Injection site reaction (6% to 22%; induration 5%; pain 4%; mass 2%)
Neuromuscular & skeletal: Musculoskeletal pain (19%)
1% to 10%:
Cardiovascular: Sinus bradycardia (3% to 7%)
Central nervous system: Dizziness (7% to 9%), depression (7%)
Endocrine & metabolic: Hyperglycemia (≤7%)
Gastrointestinal: Loose stools (6% to 9%), constipation (5% to 8%)
Neuromuscular & skeletal: Arthralgia (7% to 10%)
<1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, aortic insufficiency, cholecystitis, decreased heart rate, dysautonomia, hypersensitivity reaction, hypothyroidism, induration at injection site (persistent), injection site pruritus, malaise, mitral valve insufficiency, pancreatitis, steatorrhea
Concerns related to adverse effects:
• Cholelithiasis: May reduce gall bladder motility, leading to gall stone formation (may be dose- or duration-related); may require periodic monitoring.
• Gastrointestinal effects: Diarrhea and loose stools may occur (may affect intestinal absorption of concurrently-administered medication); abdominal pain may also occur.
• Hyper-/hypoglycemia: Inhibition of insulin and glucagon secretion may affect glucose regulation, leading to hyper-/hypoglycemia. Carefully monitor blood glucose levels with the initiation of therapy and with dosage alterations. Use with caution in patients with diabetes; may require dosage adjustments in antidiabetic therapy.
• Hypersensitivity: Allergic reactions, including angioedema and anaphylaxis, have been reported.
• Thyroid disorders: Decreases (slight) in thyroid function have been observed during treatment for acromegaly; monitor thyroid function tests if clinically indicated. The incidence of clinical hypothyroidism is rare.
• Cardiac disorders: Bradycardia, sinus bradycardia, and hypertension have been observed with therapy. Use with caution in patients with preexisting cardiac disease; monitor heart rate. Patients without preexisting cardiac disease may experience a decrease in heart rate though not to the level of bradycardia. Appropriate medical therapy should be initiated if patients develop symptomatic bradycardia.
• Hepatic impairment: Use with caution in patients with acromegaly with moderate to severe hepatic impairment (systemic exposure may be increased); lower doses are recommended at therapy initiation. Lanreotide has not been studied in patients with neuroendocrine tumors with hepatic impairment.
• Renal impairment: Use with caution in patients with acromegaly with moderate to severe renal impairment; lower initial doses are recommended.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) at 3 months and as clinically indicated in acromegaly patients (obtain levels 6 weeks after dose adjustment when switching to extended-interval dosing); blood glucose, glycemic control and antidiabetic regimen (patients with diabetes mellitus) should be assessed following initiation, then periodically or following dosage adjustments; thyroid function (where clinically indicated); heart rate, gallbladder monitoring if clinically indicated; routine gallbladder ultrasound is not considered necessary (Endocrine Society [Katznelson 2014]).
Information related to the use of lanreotide in pregnancy is limited (deMenis 1999; Teltayev 2017) and it is recommended to discontinue therapy during pregnancy (Endocrine Society [Katznelson 2014]). If treatment for acromegaly is required during pregnancy for worsening symptoms (eg, headaches or evidence of tumor growth), alternative agents are recommended. Monitoring of insulin-like growth factor 1 (IGF-1) and/or growth hormone (GH) is not recommended during pregnancy, as an active placental GH variant present in maternal blood limits the usefulness of the results (Endocrine Society [Katznelson 2014]).
Because normalization of IGF-1 and GH may restore fertility in women with acromegaly, women of childbearing potential should use adequate contraception during treatment. The Endocrine Society suggests discontinuing long-acting formulations of somatostatin analogs approximately 2 months prior to a planned pregnancy; short-acting octreotide may be used until conception if needed (Endocrine Society [Katznelson 2014]).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience abdominal pain, flatulence, nausea, vomiting, diarrhea, constipation, joint pain, muscle pain, muscle spasm, injection site pain or irritation, or weight loss. Have patient report immediately to prescriber signs of high blood sugar (confusion, fatigue, increased thirst, increased hunger, polyuria, flushing, fast breathing, or breath that smells like fruit), signs of low blood sugar (dizziness, headache, fatigue, feeling weak, shaking, tachycardia, confusion, increased hunger, or sweating), signs of gallstones (pain in the upper right abdominal area, right shoulder area, or between the shoulder blades; jaundice; or fever with chills), severe dizziness, passing out, severe headache, vision changes, signs of thyroid problems (change in weight without trying, anxiety, agitation, feeling very weak, hair thinning, depression, neck swelling, difficulty focusing, inability handling heat or cold, menstrual changes, tremors, or sweating), angina, confusion, memory impairment, bradycardia, depression, shortness of breath, flushing, or severe loss of strength and energy (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about lanreotide
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 1 Review
- Drug class: somatostatin and somatostatin analogs
Other brands: Somatuline Depot